In yesterday’s Wall Street session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares traded at $11.40, down -4.20% from the previous session.
IOVA stock price is now 28.32% away from the 50-day moving average and 15.49% away from the 200-day moving average. The market capitalization of the company currently stands at $3.46B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $19 to $10, Piper Sandler Downgraded its rating from Overweight to Neutral for Iovance Biotherapeutics Inc (NASDAQ: IOVA). On November 20, 2023, Goldman recently initiated its ‘Buy’ rating on the stock quoting a target price of $12, while ‘Barclays’ rates the stock as ‘Overweight’
In other news, MCPEAK MERRILL A, Director bought 250,000 shares of the company’s stock on Feb 20 ’24. The stock was bought for $2,287,500 at an average price of $9.15. Upon completion of the transaction, the Director now directly owns 320,150 shares in the company, valued at $3.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20 ’24, Director Dukes Iain D. bought 32,000 shares of the business’s stock. A total of $292,800 was incurred on buying the stock at an average price of $9.15. This leaves the insider owning 54,000 shares of the company worth $0.62 million. A total of 20.12% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $3.21 and a high of $18.33. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 5.15, and a quick ratio of 4.85. The fifty day moving average price for IOVA is $8.9488 and a two-hundred day moving average price translates $9.9069 for the stock.
The latest earnings results from Iovance Biotherapeutics Inc (NASDAQ: IOVA) was released for 2024-06-30. The net profit margin was -1343.27% and return on equity was -65.36% for IOVA. The company reported revenue of $31.11 million for the quarter, compared to $0.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 12969.75 percent.
